Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Operating Leases (2019 - 2025)

Denali Therapeutics (DNLI) has disclosed Operating Leases for 7 consecutive years, with $38.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases changed 0.0% to $38.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $38.8 million, a 0.0% change, with the full-year FY2024 number at $36.7 million, down 18.47% from a year prior.
  • Operating Leases was $38.8 million for Q3 2025 at Denali Therapeutics, up from $32.1 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $67.8 million in Q1 2021 to a low of $32.1 million in Q2 2025.
  • A 5-year average of $50.5 million and a median of $53.0 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: rose 0.0% in 2024, then tumbled 34.14% in 2025.
  • Denali Therapeutics' Operating Leases stood at $58.6 million in 2021, then fell by 9.43% to $53.0 million in 2022, then dropped by 15.18% to $45.0 million in 2023, then decreased by 18.47% to $36.7 million in 2024, then rose by 5.94% to $38.8 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Operating Leases are $38.8 million (Q3 2025), $32.1 million (Q2 2025), and $34.4 million (Q1 2025).